Featuring perspectives from Dr Mitesh J Borad and Dr Amit Mahipal, including the following topics:

• Introduction (0:00)
• Targeted Therapeutic Approaches for Patients with Biliary Tract Cancers (BTCs) — Dr Mahipal (4:59)
• Integration of Immune Checkpoint Inhibitors into Current BTC Management — Dr Borad (32:16)

CME information and select publications

Featuring perspectives from Ms Marianne J Davies, Dr Edward B Garon, Ms Marissa Marti-Smith and Dr Tiffany A Traina, including the following topics:

• Introduction (0:00)
• Overview of Antibody-Drug Conjugates (ADCs) (4:40)
• Trastuzumab Deruxtecan (T-DXd) in Patients with HER2-Positive Metastatic Breast Cancer (mBC) with and without Brain Metastases (12:40)
• Role of ADCs for Patients with ER-Positive mBC (35:09)
• T-DXd in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) with HER2 Alterations (52:20)
• Emerging Role of ADCs for Patients with Progressive EGFR-Mutant NSCLC (1:12:20)

NCPD information and select publications

Featuring an interview with Dr Adam M Brufsky, including the following topics:

• Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00)
• Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52)
• Clinical Investigator Survey Results (10:05)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics:

• Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00)
• Comparing safety profiles of CDK4/6 inhibitors (9:49)
• Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06)
• Real-world evidence with CDK4/6 inhibitors (27:31)

CME information and select publications

Featuring an interview with Dr William K Oh, including the following topics:

• Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
• Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
• Radiopharmaceuticals for the treatment of mCRPC (16:53)
• Available data on cabozantinib for mCRPC (24:38)
• Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
• Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
• Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
• Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
• Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
• Data surrounding adjuvant immunotherapy for MIBC (38:07)
• Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
• Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
• Implementation of emerging data in the treatment landscape of UC (41:56)

CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics:

• Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00)
• Clinical Data Available with Mosunetuzumab for R/R FL (1:54)
• Clinical Data Available with Epcoritamab for R/R FL (4:54)
• Clinical Data Available with Odronextamab for R/R FL (6:53)
• Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34)
• Practical Considerations in the Administration of Bispecific Antibodies (15:21)
• The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34)
• Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34)
• Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24)
• Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14)
• Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48)

CME information and select publications

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics:

• Introduction (0:00)
• Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42)
• Promising Novel Agents in Clinical Development; EGFR Exon 20 Mutation-Positive NSCLC — Dr Goldman (37:25)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Virginia F Borges, Dr Harold J Burstein and Dr Joyce O’Shaughnessy, including the following topics:

• Introduction (0:00)
• HER2-Positive Breast Cancer — Dr O’Shaughnessy (3:13)
• Triple-Negative Breast Cancer — Dr Bardia (32:56)
• Personalizing Adjuvant Therapy for Patients with HR-Positive Breast Cancer — Dr Borges (57:35)
• Current Role of CDK4/6 Inhibitors in the Localized Setting — Dr Burstein (1:25:15)

CME information and select publications